Results from the core phase of the open-label, Phase 3 ACROINNOVA 2 trial: CAM2029, a subcutaneous octreotide depot, achieves sustained, long-term biochemical control in acromegaly

Somatuline Depot (lanreotide prolonged-release subcutaneous) - Ipsen

Oclaiz (octreotide subcutaneous depot) - Camurus

https://ese-hormonesdistribute.m-anage.com/from.storage?image=q5B08HqJEWT974SjeAc7JiVYKJoU5EkcD8GodNVeUOQB3aJOVZyB3kKUpidEuKw90

Joanna L. Spencer-Segal * 1; Julie M. Silverstein 2; Aleksandra Gilis-Januszewska 3; Guzin Fidan Yaylali 4; Elena Isaeva 5; Monica R. Gadelha 6; Beverly M.K. Biller 7; Pietro Maffei 8; Maria Fleseriu 9; Alberto M. Pedroncelli 10; Jacob Råstam 10; Maria Harrie 10; Agneta Svedberg 10; Fredrik Tiberg 10; Diego Ferone 11

Apr 5, 2025